SLC5A2 and stage 5 chronic kidney disease: Both, the CREDENCE and the DAPA-CKD trials showed that among CKD patients, the use of SGLT-2 inhibitors could prevent or delay the development of kidney complications, including end-stage renal disease [9, 10].